SlideShare une entreprise Scribd logo

Sirolimus

•
•
edwinchowyw
edwinchowyw

Dr Lee Han Wei

TechnologieArt & Photos
1  sur  63
Mamalian Target of Rapamycin inhibitor Sirolimus
Mamalian Target of Rapamycin inhibitor Sirolimus
Contents ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Most isolated island in the world Located about 2400 Km from both Tahiti and Chile Today, the land, people, and Language is referred as “RAPA NUI” Rapa was found in Easter Island Rapa Nui - Island flag http://en.wikipedia.org/wiki/Easter_island
 
Pharmacology Pharmacokinetics Pharmacodynamics Sirolimus
Structure and mechanism of action Sirolimus
Systematic (IUPAC) name (3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S, 26R,27R,34aS)-9,10,12,13,14,21,22,23,24,25,26, 27,32,33,34,34a-hexadecahydro-9,27-dihydroxy-3- [(1R)-2-[(1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl]- 1-methylethyl]-10,21-dimethoxy-6,8,12,14,20,26- hexamethyl-23,27-epoxy-3H-pyrido[2,1-c][1,4]- oxaazacyclohentriacontine-1,5,11,28,29 (4H,6H,31H)-pentone http://en.wikipedia.org/wiki/Rapamycin ,[object Object],[object Object],[object Object],[object Object]
 
Mechanism of action ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Galat A, Metcalf S. Prog in Biophys Mol Bio . 1995 Wiederrecht G, et al. Progress in Cell Cycle Research . 1995 Liu J, et al. Cell . 1991 Flanagan WM, et al. Nature . 1991 McCaffrey PG, et al. J Biol Chem . 1993
 
 
 
 
mTOR Is a Critical Kinase in Cell Cycle Progression Adapted from Wyeth Research. Subcommittee of the Antiviral Advisory Committee on Immunosuppressive Drugs. Jan 24, 2002 p70 S6 kinase Ribosome Protein synthesis S6 DNA synthesis Cyclin E cdk2 P27 P P Translation activation eIF-4E phas-1 mTOR IL-2, IL-15 Co-stimulatory pathway FKBP12 RAPA
Effects of Sirolimus on T Cells, B Cells, and Smooth Muscle Cells 16 CELL STIMULUS FUNCTION T Cell B Cell Mitogen antigen anti-CD3, CD28 IL-2, 15 IL-2, 3, 4, 5, GM-CSF, INF-  IL-4 Pokeweed mitogen, anti-Ig, LPS IgE Y Y Y IgA IgM IgG SMC fibroblasts Growth factors Migration Y = FKBP 12: Sirolimus/TOR complex
FKBP ,[object Object],[object Object],[object Object],[object Object]
 
Mammalian target of rapamycin ,[object Object],[object Object],[object Object],[object Object],http://en.wikipedia.org/wiki/Mammalian_target_of_rapamycin mTOR has been shown to function as the catalytic subunit of two distinct molecular complexes in cells.
mTOR has been shown to function as the catalytic subunit of two distinct molecular complexes in cells.
Sirolimus Demonstrates Anti-Proliferative Activity Against a Variety of Cell Types ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Chen J et al. Proc Am Assoc Cancer Res . 1997;38:63-64. Cao W, et al. Transplantation. 1995;59:390-395. Marx SO, et al. Circ Res. 1995;76:412-417. Nair RV, et al. Transplant Proc. 1997;29:614-615. Mohacsi PJ et al. J Heart and Lung Transplant. 1997;16:484-492.
Effect of Sirolimus on Apoptosis ,[object Object],[object Object],[object Object],Dai Z, et al. J. Immunol. 1998;161:1659-1663. Shi Y, et al. Nature. 1989;339:625-626. Bierer BE, Proc Natl Acad Sci . 1990;87:9231-9235.
Animal studies
 
 
 
 
 
Sirolimus Inhibits Angiogenesis ,[object Object],[object Object],[object Object],[object Object],Guba et al. Nature Med. 2002;8:128-135
Sirolimus: Anti-Angiogenic Activity in Mouse Model Guba et al. Nature Med. 2002;8:128-135
Sirolimus: Anti-Angiogenic Activity in Mouse Model Guba et al. Nature Med. 2002;8:128-135
Pharmacokinetics Sirolimus RAPAMUNE ®
 
 
 
 
 
 
mTORi - CNI sparing regime ,[object Object],[object Object]
Stallone et al 2003 ,[object Object],[object Object],[object Object],[object Object],[object Object],Stallone G: Early withdrawal of cyclosporine A improves 1-year kidney graft structure and function in sirolimus-treated patients. Transplantation 2003 Reduce the impact of CNI by sirolimus
Stallone et al 2003 ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Stallone G: Early withdrawal of cyclosporine A improves 1-year kidney graft structure and function in sirolimus-treated patients. Transplantation 2003 Reduce the impact of CNI by sirolimus
Gonwa et al 2002 ,[object Object],[object Object],[object Object],[object Object],[object Object],Gonwa GA; for the Sirolimus Renal Function Study Group: Improved renal function in sirolimus-treated renal transplant patients after early cyclosporine elimination. Transplantation 2002 Reduce the impact of CNI by sirolimus
Gonwa et al 2002 ,[object Object],[object Object],[object Object],[object Object],Gonwa GA; for the Sirolimus Renal Function Study Group: Improved renal function in sirolimus-treated renal transplant patients after early cyclosporine elimination. Transplantation 2002 Reduce the impact of CNI by sirolimus
Oberbauer et al 2003 ,[object Object],[object Object],[object Object],[object Object],[object Object],Reduce the impact of CNI by sirolimus Oberbauer R; for the Rapamune Maintenance Regimen Study Group: Long-term improvement in renal function with sirolimus after early cyclosporine withdrawal in renal transplant recipients: 2-year results of the Rapamune Maintenance Regimen Study. Transplantation 2003
Oberbauer et al 2003 ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Reduce the impact of CNI by sirolimus Oberbauer R; for the Rapamune Maintenance Regimen Study Group: Long-term improvement in renal function with sirolimus after early cyclosporine withdrawal in renal transplant recipients: 2-year results of the Rapamune Maintenance Regimen Study. Transplantation 2003
Oberbauer et al 2003 ,[object Object],[object Object],[object Object],[object Object],[object Object],Reduce the impact of CNI by sirolimus Oberbauer R; for the Rapamune Maintenance Regimen Study Group: Long-term improvement in renal function with sirolimus after early cyclosporine withdrawal in renal transplant recipients: 2-year results of the Rapamune Maintenance Regimen Study. Transplantation 2003
Kreis et al 2004 ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Reduce the impact of CNI by sirolimus Kreis H, Oberbauer R; for the Rapamune Maintenance Regimen Trial: Long-term benefits with sirolimus-based therapy after early cyclosporine withdrawal. J Am Soc Nephrol 2004
Baboolal et al 2004 ,[object Object],[object Object],[object Object],Reduce the impact of CNI by sirolimus Baboolal K: A phase III prospective, randomized study to evaluate concentration-controlled sirolimus (rapamune) with cyclosporine dose minimization or elimination at six months in de novo renal allograft recipients. Transplantation 75: 1404–1408, 2003
Mulay et al 2006 ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Reduce the impact of CNI by sirolimus Conversion from Calcineurin Inhibitors to Sirolimus for Chronic Allograft Dysfunction: A Systemic Review of the Evidence Muray et al. Transplantation. 82(9):1153-1162, November 15, 2006.
Change from baseline in creatinine clearance after conversion to sirolimus. (A) Randomized controlled trials. (B) Nonrandomized studies. CI, confidence interval; MD, mean difference in change in creatinine clearance in ml/min from baseline between conversion and control arm; MC, mean change in creatinine clearance in mL/min from baseline. Mulay e tal . Transplantation. 82(9):1153-1162, November 15, 2006.
Mulay et al 2006 ,[object Object],[object Object],[object Object],Reduce the impact of CNI by sirolimus Muray et al. Transplantation. 82(9):1153-1162, November 15, 2006. Conversion from Calcineurin Inhibitors to Sirolimus for Chronic Allograft Dysfunction: A Systemic Review of the Evidence
Flechner et al 2007 ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Reduce the impact of CNI by sirolimus Flechner et al. Transplantation:Volume 83(7)15 April 2007: 883-892 Kidney Transplantation With Sirolimus and Mycophenolate Mofetil-Based Immunosuppression: 5-Year Results of a Randomized Prospective Trial Compared to Calcineurin Inhibitor Drugs
Flechner et al 2007 ,[object Object],[object Object],[object Object],[object Object],[object Object],Reduce the impact of CNI by sirolimus Flechner et al. Transplantation:Volume 83(7)15 April 2007: 883-892 Kidney Transplantation With Sirolimus and Mycophenolate Mofetil-Based Immunosuppression: 5-Year Results of a Randomized Prospective Trial Compared to Calcineurin Inhibitor Drugs
Flechner et al 2007 ,[object Object],[object Object],Reduce the impact of CNI by sirolimus Flechner et al. Transplantation:Volume 83(7)15 April 2007: 883-892 Kidney Transplantation With Sirolimus and Mycophenolate Mofetil-Based Immunosuppression: 5-Year Results of a Randomized Prospective Trial Compared to Calcineurin Inhibitor Drugs
Side effects
Delayed graft function ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Lieberthal W et al: Role of cell-cycle arrest and apoptosis of tubular cells. Am J Physiol Renal Physiol 2001 Smith KD et: Delayed graft function and cast nephropathy associated with tacrolimus plus rapamycin use. J Am Soc Nephrol 2003 McTaggart RA et al: Sirolimus prolongs recovery from delayed graft function after cadaveric renal transplantation. Am J Transplant 2003
Delayed graft function ,[object Object],[object Object],[object Object],Stallone G et al: Addition of sirolimus to cyclosporine delays the recovery from delayed graft function but does not affect 1-year graft function. J Am Soc Nephrol 2004
Proteinuria ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Perlman A et al: Clinically significant proteinuria following the administration of sirolimus to renal transplant recipients. J Am Soc Nephrol 2003 Hadaya K et al: Conversion to sirolimus after renal transplantation: High failure rate due to nephrotic proteinuria and other adverse events. J Am Soc Nephrol 2003
Other side effects ,[object Object],[object Object],[object Object],[object Object],[object Object],Valente JF et al: Comparison of sirolimus vs. mycophenolate mofetil on surgical complications and wound healing in adult kidney transplantation. Am J Transplant 2003 Flechner SM et al: The impact of sirolimus, mycophenolate mofetil, cyclosporine, azathioprine, and steroids on wound healing in 513 kidney-transplant recipients. Transplantation 2003
Other side effects ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Fritsche L et al. Am J Transplant 2004 Haydar AA et al. Am J Transplant 2004 Paramesh AS et al. Transplantation 2004
Everolimus ,[object Object],[object Object],[object Object],[object Object],[object Object]
 
 

Recommandé

Mtor inhibitors
Mtor inhibitorsMtor inhibitors
Mtor inhibitorsDr. Prem Mohan Jha
 
Sirolimus ppt
Sirolimus pptSirolimus ppt
Sirolimus pptshiva ranjini balamurugan
 
Tacrolimus
TacrolimusTacrolimus
TacrolimusDr Asish Kumar Saha
 
CAR- T Cell
CAR- T CellCAR- T Cell
CAR- T CellAchyut Bora
 
Hemopoietic growth factors
Hemopoietic growth factorsHemopoietic growth factors
Hemopoietic growth factorsPrasit Chanarat
 
TYROSINE KINASE INHIBITORS
TYROSINE KINASE INHIBITORSTYROSINE KINASE INHIBITORS
TYROSINE KINASE INHIBITORSyerroju vijay
 
Immunosuppressive drugs
Immunosuppressive drugsImmunosuppressive drugs
Immunosuppressive drugsChulalongkorn Allergy and Clinical Immunology Research Group
 
Drugs transporters
Drugs transportersDrugs transporters
Drugs transportersalaa essa
 

Recommandé

Mtor inhibitors
Mtor inhibitorsMtor inhibitors
Mtor inhibitorsDr. Prem Mohan Jha
 
Sirolimus ppt
Sirolimus pptSirolimus ppt
Sirolimus pptshiva ranjini balamurugan
 
Tacrolimus
TacrolimusTacrolimus
TacrolimusDr Asish Kumar Saha
 
CAR- T Cell
CAR- T CellCAR- T Cell
CAR- T CellAchyut Bora
 
Hemopoietic growth factors
Hemopoietic growth factorsHemopoietic growth factors
Hemopoietic growth factorsPrasit Chanarat
 
TYROSINE KINASE INHIBITORS
TYROSINE KINASE INHIBITORSTYROSINE KINASE INHIBITORS
TYROSINE KINASE INHIBITORSyerroju vijay
 
Immunosuppressive drugs
Immunosuppressive drugsImmunosuppressive drugs
Immunosuppressive drugsChulalongkorn Allergy and Clinical Immunology Research Group
 
Drugs transporters
Drugs transportersDrugs transporters
Drugs transportersalaa essa
 
Tyrosine kinase inhibitors
Tyrosine kinase inhibitorsTyrosine kinase inhibitors
Tyrosine kinase inhibitorsAhmad AlJifri
 
Immunosuppressive Drugs
Immunosuppressive DrugsImmunosuppressive Drugs
Immunosuppressive DrugsChulalongkorn Allergy and Clinical Immunology Research Group
 
Recent advances in the Anticancer treatment
Recent advances in the Anticancer treatmentRecent advances in the Anticancer treatment
Recent advances in the Anticancer treatmentDr. Siddhartha Dutta
 
M tor inhibitors pharmacology and complications
M tor inhibitors pharmacology and complicationsM tor inhibitors pharmacology and complications
M tor inhibitors pharmacology and complicationsPediatric Nephrology
 
calcineurin inhibitors, friend or foe
calcineurin inhibitors, friend or foecalcineurin inhibitors, friend or foe
calcineurin inhibitors, friend or foedrsalwa22000
 
Haematopoietic growth factors
Haematopoietic growth factorsHaematopoietic growth factors
Haematopoietic growth factorsmuthulakshmi623285
 
Multidrug Resistance protein
Multidrug Resistance proteinMultidrug Resistance protein
Multidrug Resistance proteinBharati vidyapeeth college of pharmacy, kolhapur
 
COLISTIN
COLISTINCOLISTIN
COLISTINAMITH SREEDHARAN
 
Chapter 24 tyrosine kinase inhibitors
Chapter 24 tyrosine kinase inhibitorsChapter 24 tyrosine kinase inhibitors
Chapter 24 tyrosine kinase inhibitorsNilesh Kucha
 
Immunosuppressants
ImmunosuppressantsImmunosuppressants
ImmunosuppressantsZulcaif Ahmad
 
Alkylating Agents & Anti-metabolites Chemotherapy
Alkylating Agents & Anti-metabolites ChemotherapyAlkylating Agents & Anti-metabolites Chemotherapy
Alkylating Agents & Anti-metabolites ChemotherapyAaditya Prakash
 
Pharmacogenomics
PharmacogenomicsPharmacogenomics
Pharmacogenomicsshabrelhan
 
Chapter 24.1 kinase inhibitors and monoclonal antibodies
Chapter 24.1 kinase inhibitors and monoclonal antibodiesChapter 24.1 kinase inhibitors and monoclonal antibodies
Chapter 24.1 kinase inhibitors and monoclonal antibodiesNilesh Kucha
 
Car tcell therapy
Car tcell therapyCar tcell therapy
Car tcell therapypreetika pradhan
 
CAR T-cell Therapy_A New Era in Cancer Immunotherapy
CAR T-cell Therapy_A New Era in Cancer ImmunotherapyCAR T-cell Therapy_A New Era in Cancer Immunotherapy
CAR T-cell Therapy_A New Era in Cancer ImmunotherapyTuhin Samanta
 
Drug transporters
Drug transportersDrug transporters
Drug transporterschandiniyrao
 
Car t cell tumor board
Car t cell tumor boardCar t cell tumor board
Car t cell tumor boardVenkata pradeep babu koyyala
 
Compartment modeling ppt
Compartment modeling pptCompartment modeling ppt
Compartment modeling pptbinu anand
 
Pharmacotherapy of tuberculosis
Pharmacotherapy of tuberculosisPharmacotherapy of tuberculosis
Pharmacotherapy of tuberculosisNaser Tadvi
 
Monoclonal Antibodies and their role in Pharmacology
Monoclonal Antibodies and their role in Pharmacology Monoclonal Antibodies and their role in Pharmacology
Monoclonal Antibodies and their role in Pharmacology Govt Medical College & Hospital, Sector-32
 
Addressing Imatinib-resistant CML
Addressing Imatinib-resistant CMLAddressing Imatinib-resistant CML
Addressing Imatinib-resistant CMLVEAB
 
Immunosupression - A back bone in the success of liver transplantation
Immunosupression - A back bone in the success of liver transplantationImmunosupression - A back bone in the success of liver transplantation
Immunosupression - A back bone in the success of liver transplantationBhavin Vasavada
 

Contenu connexe

Tendances

Tyrosine kinase inhibitors
Tyrosine kinase inhibitorsTyrosine kinase inhibitors
Tyrosine kinase inhibitorsAhmad AlJifri
 
Recent advances in the Anticancer treatment
Recent advances in the Anticancer treatmentRecent advances in the Anticancer treatment
Recent advances in the Anticancer treatmentDr. Siddhartha Dutta
 
M tor inhibitors pharmacology and complications
M tor inhibitors pharmacology and complicationsM tor inhibitors pharmacology and complications
M tor inhibitors pharmacology and complicationsPediatric Nephrology
 
calcineurin inhibitors, friend or foe
calcineurin inhibitors, friend or foecalcineurin inhibitors, friend or foe
calcineurin inhibitors, friend or foedrsalwa22000
 
Chapter 24 tyrosine kinase inhibitors
Chapter 24 tyrosine kinase inhibitorsChapter 24 tyrosine kinase inhibitors
Chapter 24 tyrosine kinase inhibitorsNilesh Kucha
 
Alkylating Agents & Anti-metabolites Chemotherapy
Alkylating Agents & Anti-metabolites ChemotherapyAlkylating Agents & Anti-metabolites Chemotherapy
Alkylating Agents & Anti-metabolites ChemotherapyAaditya Prakash
 
Pharmacogenomics
PharmacogenomicsPharmacogenomics
Pharmacogenomicsshabrelhan
 
Chapter 24.1 kinase inhibitors and monoclonal antibodies
Chapter 24.1 kinase inhibitors and monoclonal antibodiesChapter 24.1 kinase inhibitors and monoclonal antibodies
Chapter 24.1 kinase inhibitors and monoclonal antibodiesNilesh Kucha
 
CAR T-cell Therapy_A New Era in Cancer Immunotherapy
CAR T-cell Therapy_A New Era in Cancer ImmunotherapyCAR T-cell Therapy_A New Era in Cancer Immunotherapy
CAR T-cell Therapy_A New Era in Cancer ImmunotherapyTuhin Samanta
 
Compartment modeling ppt
Compartment modeling pptCompartment modeling ppt
Compartment modeling pptbinu anand
 
Pharmacotherapy of tuberculosis
Pharmacotherapy of tuberculosisPharmacotherapy of tuberculosis
Pharmacotherapy of tuberculosisNaser Tadvi
 

Tendances (20)

Tyrosine kinase inhibitors
Tyrosine kinase inhibitorsTyrosine kinase inhibitors
Tyrosine kinase inhibitors
 
Immunosuppressive Drugs
Immunosuppressive DrugsImmunosuppressive Drugs
Immunosuppressive Drugs
 
Recent advances in the Anticancer treatment
Recent advances in the Anticancer treatmentRecent advances in the Anticancer treatment
Recent advances in the Anticancer treatment
 
M tor inhibitors pharmacology and complications
M tor inhibitors pharmacology and complicationsM tor inhibitors pharmacology and complications
M tor inhibitors pharmacology and complications
 
calcineurin inhibitors, friend or foe
calcineurin inhibitors, friend or foecalcineurin inhibitors, friend or foe
calcineurin inhibitors, friend or foe
 
Haematopoietic growth factors
Haematopoietic growth factorsHaematopoietic growth factors
Haematopoietic growth factors
 
Multidrug Resistance protein
Multidrug Resistance proteinMultidrug Resistance protein
Multidrug Resistance protein
 
COLISTIN
COLISTINCOLISTIN
COLISTIN
 
Chapter 24 tyrosine kinase inhibitors
Chapter 24 tyrosine kinase inhibitorsChapter 24 tyrosine kinase inhibitors
Chapter 24 tyrosine kinase inhibitors
 
Immunosuppressants
ImmunosuppressantsImmunosuppressants
Immunosuppressants
 
Alkylating Agents & Anti-metabolites Chemotherapy
Alkylating Agents & Anti-metabolites ChemotherapyAlkylating Agents & Anti-metabolites Chemotherapy
Alkylating Agents & Anti-metabolites Chemotherapy
 
Pharmacogenomics
PharmacogenomicsPharmacogenomics
Pharmacogenomics
 
Chapter 24.1 kinase inhibitors and monoclonal antibodies
Chapter 24.1 kinase inhibitors and monoclonal antibodiesChapter 24.1 kinase inhibitors and monoclonal antibodies
Chapter 24.1 kinase inhibitors and monoclonal antibodies
 
Car tcell therapy
Car tcell therapyCar tcell therapy
Car tcell therapy
 
CAR T-cell Therapy_A New Era in Cancer Immunotherapy
CAR T-cell Therapy_A New Era in Cancer ImmunotherapyCAR T-cell Therapy_A New Era in Cancer Immunotherapy
CAR T-cell Therapy_A New Era in Cancer Immunotherapy
 
Drug transporters
Drug transportersDrug transporters
Drug transporters
 
Car t cell tumor board
Car t cell tumor boardCar t cell tumor board
Car t cell tumor board
 
Compartment modeling ppt
Compartment modeling pptCompartment modeling ppt
Compartment modeling ppt
 
Pharmacotherapy of tuberculosis
Pharmacotherapy of tuberculosisPharmacotherapy of tuberculosis
Pharmacotherapy of tuberculosis
 
Monoclonal Antibodies and their role in Pharmacology
Monoclonal Antibodies and their role in Pharmacology Monoclonal Antibodies and their role in Pharmacology
Monoclonal Antibodies and their role in Pharmacology
 

Similaire à Sirolimus

Addressing Imatinib-resistant CML
Addressing Imatinib-resistant CMLAddressing Imatinib-resistant CML
Addressing Imatinib-resistant CMLVEAB
 
Immunosupression - A back bone in the success of liver transplantation
Immunosupression - A back bone in the success of liver transplantationImmunosupression - A back bone in the success of liver transplantation
Immunosupression - A back bone in the success of liver transplantationBhavin Vasavada
 
Immunosupression -A backbone to the success of liver transplantation
Immunosupression -A backbone to the success of liver transplantationImmunosupression -A backbone to the success of liver transplantation
Immunosupression -A backbone to the success of liver transplantationBhavin Vasavada
 
Newer Chemotherapy agents and renal toxicity
Newer Chemotherapy agents and renal toxicityNewer Chemotherapy agents and renal toxicity
Newer Chemotherapy agents and renal toxicitykdj200
 
Crizotinib a8081001 asco 2010 slides
Crizotinib a8081001 asco 2010 slides Crizotinib a8081001 asco 2010 slides
Crizotinib a8081001 asco 2010 slides coolesanum
 
Metastatic bone disease: An old dogma and a new insight
Metastatic bone disease: An old dogma and a new insightMetastatic bone disease: An old dogma and a new insight
Metastatic bone disease: An old dogma and a new insightMohamed Abdulla
 
Pathophysiology of Metastatic Bone Disease and the Role of Bisphosphonates
Pathophysiology of Metastatic Bone Disease and the Role of BisphosphonatesPathophysiology of Metastatic Bone Disease and the Role of Bisphosphonates
Pathophysiology of Metastatic Bone Disease and the Role of Bisphosphonatesshabeel pn
 
MicroRNAs in kidney development and pathophysiology
MicroRNAs in kidney development and pathophysiologyMicroRNAs in kidney development and pathophysiology
MicroRNAs in kidney development and pathophysiologyChristos Argyropoulos
 
Dng uremic toxins menyet elnasr
Dng uremic toxins menyet elnasrDng uremic toxins menyet elnasr
Dng uremic toxins menyet elnasrFarragBahbah
 
Hr+ her2 neu mbc
Hr+ her2 neu mbcHr+ her2 neu mbc
Hr+ her2 neu mbcmadurai
 
El futuro del tratamiento del cáncer renal metastásico: inmunoterapia y terap...
El futuro del tratamiento del cáncer renal metastásico: inmunoterapia y terap...El futuro del tratamiento del cáncer renal metastásico: inmunoterapia y terap...
El futuro del tratamiento del cáncer renal metastásico: inmunoterapia y terap...Mauricio Lema
 
V_Hematology_Forum_Dr_Pavithran
V_Hematology_Forum_Dr_PavithranV_Hematology_Forum_Dr_Pavithran
V_Hematology_Forum_Dr_PavithranEAFO1
 
Crimson Publishers: Safety of Everolimus in Living Donor Liver Transplantatio...
Crimson Publishers: Safety of Everolimus in Living Donor Liver Transplantatio...Crimson Publishers: Safety of Everolimus in Living Donor Liver Transplantatio...
Crimson Publishers: Safety of Everolimus in Living Donor Liver Transplantatio...CrimsonGastroenterology
 
Mtor inhibitors in renal transplant
Mtor inhibitors in renal transplantMtor inhibitors in renal transplant
Mtor inhibitors in renal transplantHarsh shaH
 
Palbociclib breast cancer
Palbociclib breast cancerPalbociclib breast cancer
Palbociclib breast cancerNikos Xenidis
 
uptodate on acute kidney injury
uptodate on acute kidney injuryuptodate on acute kidney injury
uptodate on acute kidney injurySherif Mohammed
 

Similaire à Sirolimus (20)

Addressing Imatinib-resistant CML
Addressing Imatinib-resistant CMLAddressing Imatinib-resistant CML
Addressing Imatinib-resistant CML
 
Immunosupression - A back bone in the success of liver transplantation
Immunosupression - A back bone in the success of liver transplantationImmunosupression - A back bone in the success of liver transplantation
Immunosupression - A back bone in the success of liver transplantation
 
Immunosupression -A backbone to the success of liver transplantation
Immunosupression -A backbone to the success of liver transplantationImmunosupression -A backbone to the success of liver transplantation
Immunosupression -A backbone to the success of liver transplantation
 
Dr. Goy MCL
Dr. Goy MCLDr. Goy MCL
Dr. Goy MCL
 
Newer Chemotherapy agents and renal toxicity
Newer Chemotherapy agents and renal toxicityNewer Chemotherapy agents and renal toxicity
Newer Chemotherapy agents and renal toxicity
 
Crizotinib a8081001 asco 2010 slides
Crizotinib a8081001 asco 2010 slides Crizotinib a8081001 asco 2010 slides
Crizotinib a8081001 asco 2010 slides
 
Metastatic bone disease: An old dogma and a new insight
Metastatic bone disease: An old dogma and a new insightMetastatic bone disease: An old dogma and a new insight
Metastatic bone disease: An old dogma and a new insight
 
Pathophysiology of Metastatic Bone Disease and the Role of Bisphosphonates
Pathophysiology of Metastatic Bone Disease and the Role of BisphosphonatesPathophysiology of Metastatic Bone Disease and the Role of Bisphosphonates
Pathophysiology of Metastatic Bone Disease and the Role of Bisphosphonates
 
MicroRNAs in kidney development and pathophysiology
MicroRNAs in kidney development and pathophysiologyMicroRNAs in kidney development and pathophysiology
MicroRNAs in kidney development and pathophysiology
 
Dng uremic toxins menyet elnasr
Dng uremic toxins menyet elnasrDng uremic toxins menyet elnasr
Dng uremic toxins menyet elnasr
 
Professor Lars Lundell
Professor Lars LundellProfessor Lars Lundell
Professor Lars Lundell
 
CRPC management
CRPC managementCRPC management
CRPC management
 
Hr+ her2 neu mbc
Hr+ her2 neu mbcHr+ her2 neu mbc
Hr+ her2 neu mbc
 
targeted therapy
targeted therapytargeted therapy
targeted therapy
 
El futuro del tratamiento del cáncer renal metastásico: inmunoterapia y terap...
El futuro del tratamiento del cáncer renal metastásico: inmunoterapia y terap...El futuro del tratamiento del cáncer renal metastásico: inmunoterapia y terap...
El futuro del tratamiento del cáncer renal metastásico: inmunoterapia y terap...
 
V_Hematology_Forum_Dr_Pavithran
V_Hematology_Forum_Dr_PavithranV_Hematology_Forum_Dr_Pavithran
V_Hematology_Forum_Dr_Pavithran
 
Crimson Publishers: Safety of Everolimus in Living Donor Liver Transplantatio...
Crimson Publishers: Safety of Everolimus in Living Donor Liver Transplantatio...Crimson Publishers: Safety of Everolimus in Living Donor Liver Transplantatio...
Crimson Publishers: Safety of Everolimus in Living Donor Liver Transplantatio...
 
Mtor inhibitors in renal transplant
Mtor inhibitors in renal transplantMtor inhibitors in renal transplant
Mtor inhibitors in renal transplant
 
Palbociclib breast cancer
Palbociclib breast cancerPalbociclib breast cancer
Palbociclib breast cancer
 
uptodate on acute kidney injury
uptodate on acute kidney injuryuptodate on acute kidney injury
uptodate on acute kidney injury
 

Plus de edwinchowyw

Focal Glomerulosclerosis
Focal GlomerulosclerosisFocal Glomerulosclerosis
Focal Glomerulosclerosisedwinchowyw
 
Tubulointerstitial diseases
Tubulointerstitial diseasesTubulointerstitial diseases
Tubulointerstitial diseasesedwinchowyw
 
Minimal Light Microscopic Changes
Minimal Light Microscopic ChangesMinimal Light Microscopic Changes
Minimal Light Microscopic Changesedwinchowyw
 
Diffuse Proliferative GN
Diffuse Proliferative GNDiffuse Proliferative GN
Diffuse Proliferative GNedwinchowyw
 
Mesangial proliferative GN
Mesangial proliferative GNMesangial proliferative GN
Mesangial proliferative GNedwinchowyw
 
Focalproliferative Glomerulonephritis
Focalproliferative GlomerulonephritisFocalproliferative Glomerulonephritis
Focalproliferative Glomerulonephritisedwinchowyw
 
Basement Membrane Abnormalities
Basement Membrane AbnormalitiesBasement Membrane Abnormalities
Basement Membrane Abnormalitiesedwinchowyw
 
Humoral Immunity
Humoral ImmunityHumoral Immunity
Humoral Immunityedwinchowyw
 
Introduction to Renal Pathology
Introduction to Renal PathologyIntroduction to Renal Pathology
Introduction to Renal Pathologyedwinchowyw
 
Nephrotic Syndrome
Nephrotic SyndromeNephrotic Syndrome
Nephrotic Syndromeedwinchowyw
 
Dry Weight Dr Rosna
Dry Weight Dr RosnaDry Weight Dr Rosna
Dry Weight Dr Rosnaedwinchowyw
 
Bartter’S And Gittleman’S Syndromes
Bartter’S And Gittleman’S SyndromesBartter’S And Gittleman’S Syndromes
Bartter’S And Gittleman’S Syndromesedwinchowyw
 
Mycophenolate Mofetil in Primary Glomerulonephritis
Mycophenolate Mofetil in Primary GlomerulonephritisMycophenolate Mofetil in Primary Glomerulonephritis
Mycophenolate Mofetil in Primary Glomerulonephritisedwinchowyw
 
Mycophenolate Mofetil In Relapsing Lupus Nephritis
Mycophenolate Mofetil In Relapsing Lupus NephritisMycophenolate Mofetil In Relapsing Lupus Nephritis
Mycophenolate Mofetil In Relapsing Lupus Nephritisedwinchowyw
 

Plus de edwinchowyw (20)

Focal Glomerulosclerosis
Focal GlomerulosclerosisFocal Glomerulosclerosis
Focal Glomerulosclerosis
 
MPGN/MCGN
MPGN/MCGNMPGN/MCGN
MPGN/MCGN
 
Membranous GN
Membranous GNMembranous GN
Membranous GN
 
Nodular GN
Nodular GNNodular GN
Nodular GN
 
Tubulointerstitial diseases
Tubulointerstitial diseasesTubulointerstitial diseases
Tubulointerstitial diseases
 
Minimal Light Microscopic Changes
Minimal Light Microscopic ChangesMinimal Light Microscopic Changes
Minimal Light Microscopic Changes
 
Crescentic GN
Crescentic GNCrescentic GN
Crescentic GN
 
Diffuse Proliferative GN
Diffuse Proliferative GNDiffuse Proliferative GN
Diffuse Proliferative GN
 
Mesangial proliferative GN
Mesangial proliferative GNMesangial proliferative GN
Mesangial proliferative GN
 
Focalproliferative Glomerulonephritis
Focalproliferative GlomerulonephritisFocalproliferative Glomerulonephritis
Focalproliferative Glomerulonephritis
 
Basement Membrane Abnormalities
Basement Membrane AbnormalitiesBasement Membrane Abnormalities
Basement Membrane Abnormalities
 
Humoral Immunity
Humoral ImmunityHumoral Immunity
Humoral Immunity
 
Introduction to Renal Pathology
Introduction to Renal PathologyIntroduction to Renal Pathology
Introduction to Renal Pathology
 
Intro Immune
Intro ImmuneIntro Immune
Intro Immune
 
Nephrotic Syndrome
Nephrotic SyndromeNephrotic Syndrome
Nephrotic Syndrome
 
Screening
ScreeningScreening
Screening
 
Dry Weight Dr Rosna
Dry Weight Dr RosnaDry Weight Dr Rosna
Dry Weight Dr Rosna
 
Bartter’S And Gittleman’S Syndromes
Bartter’S And Gittleman’S SyndromesBartter’S And Gittleman’S Syndromes
Bartter’S And Gittleman’S Syndromes
 
Mycophenolate Mofetil in Primary Glomerulonephritis
Mycophenolate Mofetil in Primary GlomerulonephritisMycophenolate Mofetil in Primary Glomerulonephritis
Mycophenolate Mofetil in Primary Glomerulonephritis
 
Mycophenolate Mofetil In Relapsing Lupus Nephritis
Mycophenolate Mofetil In Relapsing Lupus NephritisMycophenolate Mofetil In Relapsing Lupus Nephritis
Mycophenolate Mofetil In Relapsing Lupus Nephritis
 

Dernier

Modular Monolith - a Practical Alternative to Microservices @ Devoxx UK 2024
Modular Monolith - a Practical Alternative to Microservices @ Devoxx UK 2024Modular Monolith - a Practical Alternative to Microservices @ Devoxx UK 2024
Modular Monolith - a Practical Alternative to Microservices @ Devoxx UK 2024Victor Rentea
 
Cloud Frontiers: A Deep Dive into Serverless Spatial Data and FME
Cloud Frontiers: A Deep Dive into Serverless Spatial Data and FMECloud Frontiers: A Deep Dive into Serverless Spatial Data and FME
Cloud Frontiers: A Deep Dive into Serverless Spatial Data and FMESafe Software
 
Web Form Automation for Bonterra Impact Management (fka Social Solutions Apri...
Web Form Automation for Bonterra Impact Management (fka Social Solutions Apri...Web Form Automation for Bonterra Impact Management (fka Social Solutions Apri...
Web Form Automation for Bonterra Impact Management (fka Social Solutions Apri...Jeffrey Haguewood
 
Navigating the Deluge_ Dubai Floods and the Resilience of Dubai International...
Navigating the Deluge_ Dubai Floods and the Resilience of Dubai International...Navigating the Deluge_ Dubai Floods and the Resilience of Dubai International...
Navigating the Deluge_ Dubai Floods and the Resilience of Dubai International...Orbitshub
 
Strategize a Smooth Tenant-to-tenant Migration and Copilot Takeoff
Strategize a Smooth Tenant-to-tenant Migration and Copilot TakeoffStrategize a Smooth Tenant-to-tenant Migration and Copilot Takeoff
Strategize a Smooth Tenant-to-tenant Migration and Copilot Takeoffsammart93
 
presentation ICT roal in 21st century education
presentation ICT roal in 21st century educationpresentation ICT roal in 21st century education
presentation ICT roal in 21st century educationjfdjdjcjdnsjd
 
Why Teams call analytics are critical to your entire business
Why Teams call analytics are critical to your entire businessWhy Teams call analytics are critical to your entire business
Why Teams call analytics are critical to your entire businesspanagenda
 
[BuildWithAI] Introduction to Gemini.pdf
[BuildWithAI] Introduction to Gemini.pdf[BuildWithAI] Introduction to Gemini.pdf
[BuildWithAI] Introduction to Gemini.pdfSandro Moreira
 
Polkadot JAM Slides - Token2049 - By Dr. Gavin Wood
Polkadot JAM Slides - Token2049 - By Dr. Gavin WoodPolkadot JAM Slides - Token2049 - By Dr. Gavin Wood
Polkadot JAM Slides - Token2049 - By Dr. Gavin WoodJuan lago vázquez
 
EMPOWERMENT TECHNOLOGY GRADE 11 QUARTER 2 REVIEWER
EMPOWERMENT TECHNOLOGY GRADE 11 QUARTER 2 REVIEWEREMPOWERMENT TECHNOLOGY GRADE 11 QUARTER 2 REVIEWER
EMPOWERMENT TECHNOLOGY GRADE 11 QUARTER 2 REVIEWERMadyBayot
 
Apidays New York 2024 - Accelerating FinTech Innovation by Vasa Krishnan, Fin...
Apidays New York 2024 - Accelerating FinTech Innovation by Vasa Krishnan, Fin...Apidays New York 2024 - Accelerating FinTech Innovation by Vasa Krishnan, Fin...
Apidays New York 2024 - Accelerating FinTech Innovation by Vasa Krishnan, Fin...apidays
 
Apidays New York 2024 - The value of a flexible API Management solution for O...
Apidays New York 2024 - The value of a flexible API Management solution for O...Apidays New York 2024 - The value of a flexible API Management solution for O...
Apidays New York 2024 - The value of a flexible API Management solution for O...apidays
 
AXA XL - Insurer Innovation Award Americas 2024
AXA XL - Insurer Innovation Award Americas 2024AXA XL - Insurer Innovation Award Americas 2024
AXA XL - Insurer Innovation Award Americas 2024The Digital Insurer
 
Apidays New York 2024 - Scaling API-first by Ian Reasor and Radu Cotescu, Adobe
Apidays New York 2024 - Scaling API-first by Ian Reasor and Radu Cotescu, AdobeApidays New York 2024 - Scaling API-first by Ian Reasor and Radu Cotescu, Adobe
Apidays New York 2024 - Scaling API-first by Ian Reasor and Radu Cotescu, Adobeapidays
 
Apidays New York 2024 - Passkeys: Developing APIs to enable passwordless auth...
Apidays New York 2024 - Passkeys: Developing APIs to enable passwordless auth...Apidays New York 2024 - Passkeys: Developing APIs to enable passwordless auth...
Apidays New York 2024 - Passkeys: Developing APIs to enable passwordless auth...apidays
 
Apidays New York 2024 - The Good, the Bad and the Governed by David O'Neill, ...
Apidays New York 2024 - The Good, the Bad and the Governed by David O'Neill, ...Apidays New York 2024 - The Good, the Bad and the Governed by David O'Neill, ...
Apidays New York 2024 - The Good, the Bad and the Governed by David O'Neill, ...apidays
 
Exploring the Future Potential of AI-Enabled Smartphone Processors
Exploring the Future Potential of AI-Enabled Smartphone ProcessorsExploring the Future Potential of AI-Enabled Smartphone Processors
Exploring the Future Potential of AI-Enabled Smartphone Processorsdebabhi2
 
TrustArc Webinar - Unlock the Power of AI-Driven Data Discovery
TrustArc Webinar - Unlock the Power of AI-Driven Data DiscoveryTrustArc Webinar - Unlock the Power of AI-Driven Data Discovery
TrustArc Webinar - Unlock the Power of AI-Driven Data DiscoveryTrustArc
 
Manulife - Insurer Transformation Award 2024
Manulife - Insurer Transformation Award 2024Manulife - Insurer Transformation Award 2024
Manulife - Insurer Transformation Award 2024The Digital Insurer
 
Repurposing LNG terminals for Hydrogen Ammonia: Feasibility and Cost Saving
Repurposing LNG terminals for Hydrogen Ammonia: Feasibility and Cost SavingRepurposing LNG terminals for Hydrogen Ammonia: Feasibility and Cost Saving
Repurposing LNG terminals for Hydrogen Ammonia: Feasibility and Cost SavingEdi Saputra
 

Dernier (20)

Modular Monolith - a Practical Alternative to Microservices @ Devoxx UK 2024
Modular Monolith - a Practical Alternative to Microservices @ Devoxx UK 2024Modular Monolith - a Practical Alternative to Microservices @ Devoxx UK 2024
Modular Monolith - a Practical Alternative to Microservices @ Devoxx UK 2024
 
Cloud Frontiers: A Deep Dive into Serverless Spatial Data and FME
Cloud Frontiers: A Deep Dive into Serverless Spatial Data and FMECloud Frontiers: A Deep Dive into Serverless Spatial Data and FME
Cloud Frontiers: A Deep Dive into Serverless Spatial Data and FME
 
Web Form Automation for Bonterra Impact Management (fka Social Solutions Apri...
Web Form Automation for Bonterra Impact Management (fka Social Solutions Apri...Web Form Automation for Bonterra Impact Management (fka Social Solutions Apri...
Web Form Automation for Bonterra Impact Management (fka Social Solutions Apri...
 
Navigating the Deluge_ Dubai Floods and the Resilience of Dubai International...
Navigating the Deluge_ Dubai Floods and the Resilience of Dubai International...Navigating the Deluge_ Dubai Floods and the Resilience of Dubai International...
Navigating the Deluge_ Dubai Floods and the Resilience of Dubai International...
 
Strategize a Smooth Tenant-to-tenant Migration and Copilot Takeoff
Strategize a Smooth Tenant-to-tenant Migration and Copilot TakeoffStrategize a Smooth Tenant-to-tenant Migration and Copilot Takeoff
Strategize a Smooth Tenant-to-tenant Migration and Copilot Takeoff
 
presentation ICT roal in 21st century education
presentation ICT roal in 21st century educationpresentation ICT roal in 21st century education
presentation ICT roal in 21st century education
 
Why Teams call analytics are critical to your entire business
Why Teams call analytics are critical to your entire businessWhy Teams call analytics are critical to your entire business
Why Teams call analytics are critical to your entire business
 
[BuildWithAI] Introduction to Gemini.pdf
[BuildWithAI] Introduction to Gemini.pdf[BuildWithAI] Introduction to Gemini.pdf
[BuildWithAI] Introduction to Gemini.pdf
 
Polkadot JAM Slides - Token2049 - By Dr. Gavin Wood
Polkadot JAM Slides - Token2049 - By Dr. Gavin WoodPolkadot JAM Slides - Token2049 - By Dr. Gavin Wood
Polkadot JAM Slides - Token2049 - By Dr. Gavin Wood
 
EMPOWERMENT TECHNOLOGY GRADE 11 QUARTER 2 REVIEWER
EMPOWERMENT TECHNOLOGY GRADE 11 QUARTER 2 REVIEWEREMPOWERMENT TECHNOLOGY GRADE 11 QUARTER 2 REVIEWER
EMPOWERMENT TECHNOLOGY GRADE 11 QUARTER 2 REVIEWER
 
Apidays New York 2024 - Accelerating FinTech Innovation by Vasa Krishnan, Fin...
Apidays New York 2024 - Accelerating FinTech Innovation by Vasa Krishnan, Fin...Apidays New York 2024 - Accelerating FinTech Innovation by Vasa Krishnan, Fin...
Apidays New York 2024 - Accelerating FinTech Innovation by Vasa Krishnan, Fin...
 
Apidays New York 2024 - The value of a flexible API Management solution for O...
Apidays New York 2024 - The value of a flexible API Management solution for O...Apidays New York 2024 - The value of a flexible API Management solution for O...
Apidays New York 2024 - The value of a flexible API Management solution for O...
 
AXA XL - Insurer Innovation Award Americas 2024
AXA XL - Insurer Innovation Award Americas 2024AXA XL - Insurer Innovation Award Americas 2024
AXA XL - Insurer Innovation Award Americas 2024
 
Apidays New York 2024 - Scaling API-first by Ian Reasor and Radu Cotescu, Adobe
Apidays New York 2024 - Scaling API-first by Ian Reasor and Radu Cotescu, AdobeApidays New York 2024 - Scaling API-first by Ian Reasor and Radu Cotescu, Adobe
Apidays New York 2024 - Scaling API-first by Ian Reasor and Radu Cotescu, Adobe
 
Apidays New York 2024 - Passkeys: Developing APIs to enable passwordless auth...
Apidays New York 2024 - Passkeys: Developing APIs to enable passwordless auth...Apidays New York 2024 - Passkeys: Developing APIs to enable passwordless auth...
Apidays New York 2024 - Passkeys: Developing APIs to enable passwordless auth...
 
Apidays New York 2024 - The Good, the Bad and the Governed by David O'Neill, ...
Apidays New York 2024 - The Good, the Bad and the Governed by David O'Neill, ...Apidays New York 2024 - The Good, the Bad and the Governed by David O'Neill, ...
Apidays New York 2024 - The Good, the Bad and the Governed by David O'Neill, ...
 
Exploring the Future Potential of AI-Enabled Smartphone Processors
Exploring the Future Potential of AI-Enabled Smartphone ProcessorsExploring the Future Potential of AI-Enabled Smartphone Processors
Exploring the Future Potential of AI-Enabled Smartphone Processors
 
TrustArc Webinar - Unlock the Power of AI-Driven Data Discovery
TrustArc Webinar - Unlock the Power of AI-Driven Data DiscoveryTrustArc Webinar - Unlock the Power of AI-Driven Data Discovery
TrustArc Webinar - Unlock the Power of AI-Driven Data Discovery
 
Manulife - Insurer Transformation Award 2024
Manulife - Insurer Transformation Award 2024Manulife - Insurer Transformation Award 2024
Manulife - Insurer Transformation Award 2024
 
Repurposing LNG terminals for Hydrogen Ammonia: Feasibility and Cost Saving
Repurposing LNG terminals for Hydrogen Ammonia: Feasibility and Cost SavingRepurposing LNG terminals for Hydrogen Ammonia: Feasibility and Cost Saving
Repurposing LNG terminals for Hydrogen Ammonia: Feasibility and Cost Saving
 

Sirolimus

  • 1. Mamalian Target of Rapamycin inhibitor Sirolimus
  • 2. Mamalian Target of Rapamycin inhibitor Sirolimus
  • 3.
  • 4. Most isolated island in the world Located about 2400 Km from both Tahiti and Chile Today, the land, people, and Language is referred as “RAPA NUI” Rapa was found in Easter Island Rapa Nui - Island flag http://en.wikipedia.org/wiki/Easter_island
  • 5.  
  • 7. Structure and mechanism of action Sirolimus
  • 8.
  • 9.  
  • 10.
  • 11.  
  • 12.  
  • 13.  
  • 14.  
  • 15. mTOR Is a Critical Kinase in Cell Cycle Progression Adapted from Wyeth Research. Subcommittee of the Antiviral Advisory Committee on Immunosuppressive Drugs. Jan 24, 2002 p70 S6 kinase Ribosome Protein synthesis S6 DNA synthesis Cyclin E cdk2 P27 P P Translation activation eIF-4E phas-1 mTOR IL-2, IL-15 Co-stimulatory pathway FKBP12 RAPA
  • 16. Effects of Sirolimus on T Cells, B Cells, and Smooth Muscle Cells 16 CELL STIMULUS FUNCTION T Cell B Cell Mitogen antigen anti-CD3, CD28 IL-2, 15 IL-2, 3, 4, 5, GM-CSF, INF-  IL-4 Pokeweed mitogen, anti-Ig, LPS IgE Y Y Y IgA IgM IgG SMC fibroblasts Growth factors Migration Y = FKBP 12: Sirolimus/TOR complex
  • 17.
  • 18.  
  • 19.
  • 20. mTOR has been shown to function as the catalytic subunit of two distinct molecular complexes in cells.
  • 21.
  • 22.
  • 24.  
  • 25.  
  • 26.  
  • 27.  
  • 28.  
  • 29.
  • 30. Sirolimus: Anti-Angiogenic Activity in Mouse Model Guba et al. Nature Med. 2002;8:128-135
  • 31. Sirolimus: Anti-Angiogenic Activity in Mouse Model Guba et al. Nature Med. 2002;8:128-135
  • 33.  
  • 34.  
  • 35.  
  • 36.  
  • 37.  
  • 38.  
  • 39.
  • 40.
  • 41.
  • 42.
  • 43.
  • 44.
  • 45.
  • 46.
  • 47.
  • 48.
  • 49.
  • 50. Change from baseline in creatinine clearance after conversion to sirolimus. (A) Randomized controlled trials. (B) Nonrandomized studies. CI, confidence interval; MD, mean difference in change in creatinine clearance in ml/min from baseline between conversion and control arm; MC, mean change in creatinine clearance in mL/min from baseline. Mulay e tal . Transplantation. 82(9):1153-1162, November 15, 2006.
  • 51.
  • 52.
  • 53.
  • 54.
  • 56.
  • 57.
  • 58.
  • 59.
  • 60.
  • 61.
  • 62.  
  • 63.